Apply for funding to develop a broad utility, deep genotyping and phenotyping platform capable of generating insights into patient response, adverse effects, and resistance to immunotherapy, and exemplar project(s) to demonstrate utility.

The platform will be led by a multi-organisational and multidisciplinary consortium, including at least one industry partner.

A total of £9 million (80% Full Economic cost (FEC) including relevant indexing) over four years is available with £4 million in FY 2024/25.

You must be a researcher employed at a research organisation eligible to apply for Medical Research Council (MRC) funding.

Opportunity status: Open

Funders: Medical Research Council (MRC)

Co-funders: Office of Life Sciences

Funding type: Grant

Total fund: £9,000,000

Maximum award: £9,000,000

Publication date: 9 January 2024

Opening date: 25 January 2024 9:00am UK time

Closing date: 9 May 2024 4:00pm UK time